Thursday, 5 November 2026European Markets

BALYO Stock Bullish By 10% So Far On Friday

Loading stream...

(vianews) - shares of balyo (cac 40: balyo.pa) jumped 10% to €0.58 at 11:51 est on friday, following the last session's upward trend. cac 40 is sliding 0.03% to €7,536.63, following the last session's downward trend. this seems, at the moment, a somewhat bearish trend trading session today.

balyo's last close was €0.53, 52.85% below its 52-week high of €1.12.

about balyo

balyo sa designs, develops, and markets material handling robots worldwide. the company offers robotic pallet and reach trucks, tuggers, stackers, counterbalanced stackers, very narrow aisles, and autonomous mobile robots. its products are used in intelligent pallet detection, barcode scanning, inter-building transport, push button configuration, machine interface, erp interfacing, and palletizers; and wms interface and 3d camera applications. the company serves 3pl, automotive, e-commerce, and consumer goods industries. balyo sa was founded in 2004 and is headquartered in arcueil, france.

earnings per share

as for profitability, balyo has a trailing twelve months eps of €-0.18.

volume

today's last reported volume for balyo is 411966 which is 96.98% above its average volume of 209133.

yearly top and bottom value

balyo's stock is valued at €0.58 at 11:51 est, way below its 52-week high of €1.12 and way higher than its 52-week low of €0.38.

more news about balyo (balyo.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com